BioScrip Reports Fourth Quarter and Full Year 2017 Financial Results DENVER, CO

BioScrip Reports Fourth Quarter and Full

Year 2017 Financial Results

DENVER, CO, March 8, 2018 - BioScrip,

Inc. (NASDAQ: BIOS) ("BioScrip" or the "Company"), the largest independent national provider of infusion and

home care management solutions, today announced its preliminary 2017 financial results and provided financial guidance for 2018,

subject to the completion of the Company's accounting review described below.

4Q 2017 Preliminary Highlights

2017 Preliminary Highlights

"BioScrip concluded 2017 with strong

fourth quarter financial results, delivering significant year-over-year increases in core revenue mix, gross profit margin, adjusted

EBITDA and cash provided by operating activities. Our fourth quarter adjusted EBITDA of $16.8 million, a record amount, indicates

our turnaround plan is working," said Daniel E. Greenleaf, President and Chief Executive Officer. "The initiatives

we launched in 2017 are producing strong results and continuing to build momentum. We look forward to more progress in 2018, growing

our core business and expanding our profitability, while making select investments in people, technology, and infrastructure setting

up BioScrip to have a break out year in 2019. Our expectation for 2019 is to deliver a minimum of $75 million of Adjusted EBITDA,

resulting from core revenue growth at or above market rates and continued gross margin expansion and operating expense leverage,

coupled with the benefit of the Cures Fix. As the only independent national home infusion pure play, we are uniquely positioned

to benefit as patient care increasingly migrates from higher-cost institutional settings to the home, where better outcomes are

For full year 2018, the Company is establishing

revenue guidance of $710 million to $720 million and adjusted EBITDA guidance of $54 million to $58 million. The Company expects

to incur restructuring expenses of between $5 million and $6 million in 2018, primarily reflecting costs related to redesigning

and optimizing its revenue cycle management process. The Company expects capital expenditures in 2018 to be between $12 million

and $14 million, reflecting continued maintenance capital expenditures as well anticipated investments in select branches to support

The above guidance does not reflect the

adoption of ASC 606, a new revenue accounting standard to be adopted in the first quarter of 2018, that requires certain bad debt

expenses to be reclassified as a deduction to revenue. The adoption of ASC 606 is not expected to impact the Company's reported

operating income or adjusted EBITDA. The Company expects that, as a result of adopting ASC 606, that a majority of its bad debt

expense will be reclassified as a deduction to revenue. The Company will provide updated revenue guidance to reflect the adoption

of ASC 606 when it releases its first quarter 2018 financial results.

Company's Internal Accounting

As a result of the detailed review of the

Company's financial statements performed by the Company's CFO and interim-CAO during the preparation of the Company's

financial statements for the full year 2017, the Company identified internal control deficiencies in connection with account reconciliations

for certain asset and liability accounts. The potential financial statement errors discovered to date resulting from these internal

control deficiencies do not appear to be material, but the review is ongoing. The Company, along with its external auditors, continues

to review the possible errors and, if required, will reflect any necessary revisions and may report one or more internal control

material weaknesses in its upcoming Form 10-K filing. Depending on the timing of the completion of this review, the Company may

need to delay the filing of the Form 10-K.

Separately, the Company has identified

and will report a material weakness related to certain spreadsheets used to calculate periodic adjustments to accounts that do

not impact Adjusted EBITDA, including amortization of intangible assets, equity-linked liabilities and the amortization of discounts

and deferred issuance costs of debt. The material weakness did not have any effect on the Company's 2017 financial statements.

Conference Call and Presentation

BioScrip will host a conference call and

live webcast on March 8, 2018, at 9:00 a.m. Eastern Time, to discuss its fourth quarter and full year 2017 financial results.

Interested parties may participate by dialing 877-423-9820 (US) or by accessing a link under the "Investors" section

on the Company's website at www.bioscrip.com.

An audio webcast and archive will be available

within two hours of the call's completion under the "Investors" section of the Company's website.

About BioScrip, Inc.

BioScrip, Inc. is the largest independent

national provider of infusion and home care management solutions, with approximately 2,200 teammates and nearly 80 service locations

across the U.S. BioScrip partners with physicians, hospital systems, payors, pharmaceutical manufacturers and skilled nursing facilities

to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy

and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum

of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer

service, and values that promote positive outcomes and an enhanced quality of life for those it serves.

Forward-Looking Statements -

This press release includes statements

that may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of

1995, including the statements regarding 2017 guidance, projections of certain measures of the Company's results of operations,

projections of future levels of certain charges and expenses, expectations of Home Solutions cost synergies and incremental cost

structure improvements and other statements regarding the Company's financial improvement plan and strategy and anticipated effects

of the Cures Act and the UnitedHealthcare contract. You can identify these statements by the fact that they do not relate strictly

to historical or current facts. In some cases, forward-looking statements can be identified by words such as "may," "should,"

"could," "anticipate," "estimate," "expect," "project," "outlook,"

"aim," "intend," "plan," "believe," "predict," "potential," "continue"

or comparable terms. Because such statements inherently involve risks and uncertainties, actual future results may differ materially

from those expressed or implied by such forward-looking statements. Investors are cautioned that any such forward-looking statements

are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from

those in the forward-looking statements as a result of various factors. Important factors that could cause actual results to differ

materially from those in the forward-looking statement include but are not limited to risks associated with: the Company's

ability to make principal and interest payments on our debt and unsecured notes and satisfy the other covenants contained in its

debt agreements; the Company's ability to grow its core Infusion revenues; the Company's ability to continue to execute its

financial improvement plan to reduce operating costs and focus its business on its Infusion Services segment; the Company's

ability to evaluate opportunities for improvement and implement solutions as part of its strategic review process; the success

of the Company's initiatives to mitigate the impact of the Cures Act on its business; reductions in federal, state and commercial

reimbursement for the Company's products and services; increased government regulation related to the health care and insurance

industries; as well as the risks described in the Company's periodic filings with the Securities and Exchange Commission. The Company

does not undertake any duty to update these forward-looking statements after the date hereof, even though the Company's situation

may change in the future. All of the forward-looking statements herein are qualified by these cautionary statements.

Note Regarding Use of Non-GAAP Financial

In addition to reporting financial information

in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP

financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation

or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP,

or as a substitute or alternative to cash flow from operating activities or a measure of the Company's liquidity. In addition,

the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other

companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation

and amortization, impairment of goodwill, stock-based compensation expense, and restructuring, integration and other expenses.

As part of restructuring, the Company may incur significant charges such as the write down of certain long lived assets,

temporary redundant expenses, retraining expenses, potential cash bonus payments and potential accelerated payments or terminated

costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information

regarding the performance of BioScrip's business operations and facilitates comparisons to the Company's historical

operating results. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see the attachment

to this earnings release.

BIOSCRIP, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands, except for share amounts)